The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The most frequently reported coagulation/fibrinolytic abnormality in COVID-19 is the increase in d-dimer, and its relationship with prognosis has been discussed. However, limits exist to the utility of evaluation by d-dimer alone. In addition, since the coagulation/fibrinolytic condition sometimes fluctuates within a short period of time, regular examinations in recognition of the significance of the examination are desirable. The pathophysiology of disseminated intravascular coagulation (DIC) associated with COVID-19 is very different from that of septic DIC, and both thrombotic and hemorrhagic pathologies should be noted. COVID-19 thrombosis includes macro- and microthrombosis, with diagnosis of the latter depending on markers of coagulation and fibrinolysis. Treatment of COVID-19 is classified into antiviral treatment, cytokine storm treatment, and thrombosis treatment. Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination therapy with heparin and nafamostat is expected to develop in the future. Fibrinolytic therapy and adsorption therapy require further study

血栓形成，弥散性血管内凝血（DIC）和细胞因子风暴的进展加剧了冠状病毒疾病2019（COVID-19）的病理。在COVID-19中最常报告的凝血/纤维蛋白溶解异常是d-二聚体的增加，并且已经讨论了其与预后的关系。但是，通过d进行评估的效用存在局限性-二聚体。另外，由于凝结/纤维蛋白溶解状态有时在短时间内波动，因此需要定期检查以确认检查的重要性。与COVID-19相关的弥散性血管内凝血（DIC）的病理生理学与败血性DIC的病理生理学非常不同，应注意血栓性和出血性病理。COVID-19血栓形成包括宏观血栓形成和微血栓形成，后者的诊断取决于凝血和纤维蛋白溶解的标志物。COVID-19的治疗分为抗病毒治疗，细胞因子风暴治疗和血栓形成治疗。与其提供统一的治疗方法，不如选择最适合病情严重程度和阶段的治疗方法。肝素和那法莫他的联合治疗有望在未来发展。纤溶疗法和吸附疗法需要进一步研究